Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis
Synergistic Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis in Head and Neck Cancer Patients: Randomized Controlled Clinical Trial
1 other identifier
interventional
40
1 country
2
Brief Summary
The goal of this \[ type of study: Clinical trial\] is to test effectiveness of Aloe Vera Gel and Manuka Honey in management of Radiation Induced Mucositis in head and neck cancer patients. The main question \[s\] \] is to \[ learn about, test, compare etc.\] it aims to answer are:
- 1.Is Aloe Vera Gel and Manuka Honey effective in management of Radiation Induced Mucositis?
- 2.Does Aloe Vera Gel and Manuka Honey affect the level of TGFβ1 and EGF in saliva of patients with radiation induced mucositis? participants will be asked to apply Aloe Vera Gel and Manuka Honey or saline three times daily during radiotherapy and 6 months after radiotherapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2024
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2024
CompletedFirst Submitted
Initial submission to the registry
April 20, 2024
CompletedFirst Posted
Study publicly available on registry
April 24, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedApril 24, 2024
April 1, 2024
6 months
April 20, 2024
April 20, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Change from World Health Organization Oral Toxicity Scale Grading of Oral Mucositis
World Health Organization Oral Toxicity Scale Grading of Oral Mucositis ranges from "1,2,3,4) the grade1 me
Three points: -"baseline which is at the starting of radiotherapy", -"the second of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline, while the end point is after six months of radiotherapy.
Secondary Outcomes (2)
the level of salivary transforming growth factor beta 1
Two points: -"baseline which is at the second week of radiotherapy" while -"the end of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline.
the level of salivary Epidermal Growth factor (EGF)
Two points: -"baseline which is at the second week of radiotherapy" while -"the end of the radiotherapy is at seventh week of the radiotherapy or 4-5 weeks from baseline.
Study Arms (2)
intervention group
EXPERIMENTALpatients will be given 20 mL of Manuka honey with aloe vera gel, 15 min before and after the radiotherapy. They were instructed to swallow slowly to smear the layer of honey on the oral and pharyngeal mucosa. Patients were also advised to take 20 mL of Manuka honey before sleeping in the night. This treatment protocol was followed from day 1 of radiation till 6 weeks.
Control group
PLACEBO COMPARATORpatients will be given 20 mL of 0.9% of saline 15 min before and after radiotherapy \[54\]. They will be advised to rinse saline. They will be instructed to keep saline for at least 5 min duration and then to spit it out. They will be advised to rinse 20 mL of saline in the same manner before sleeping. This treatment protocol was followed from day 1 of radiation till 6 weeks.
Interventions
a mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles.
Eligibility Criteria
You may qualify if:
- a) Patients with a confirmed histologic diagnosis of H\&N malignancy who are referred to non-palliative radiotherapy in the oral cavity.
- b) Patient who is receiving radiation therapy with IMRT or 3D techniques. c) Patients received 50-70 Gy of total radiation at the rate of 2 Gy/fraction daily and 5 fractions/week.
- d) Patient who received concurrent chemotherapy with radiotherapy e) Presence of Oral Mucositis f) Age 20-70 years old g) Willing to participate in the study. h) Able to complete the study assessments.
You may not qualify if:
- a) Have a confirmed or medically treated diabetes mellitus b) Radiotherapy within the last 6 months prior to this study c) Vulnerable patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
ain shams University
Cairo, 11565, Egypt
Fatma E.Sayed
Cairo, Egypt
MeSH Terms
Interventions
Study Officials
- STUDY DIRECTOR
Fatma E. Hassanein, PHD
lecturer
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 20, 2024
First Posted
April 24, 2024
Study Start
April 1, 2024
Primary Completion
October 1, 2024
Study Completion
January 1, 2025
Last Updated
April 24, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share